Neurocrine Biosciences, Inc.
NASDAQ:NBIXBiotechnology
-$0.71 today
- Market cap
- $16.48B
- Beta
- 0.40
- P/E (TTM)
- 23.8
- EPS (TTM)
- $6.65
Volume 1.60M
Average 1.18M
NBIX Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Neurocrine Biosciences, Inc.NASDAQ: NBIX
Gross Margin · Q3 FY2026 · quarter ended Sep 2026
Gross margin narrows to 97.6%
Gross margin was 97.6% in Q3 FY2026, down 0.6 pp from a year earlier. On a trailing-twelve-month basis it was 97.8%, down 0.6 pp year over year. Over 3 fiscal years it narrowed by 0.3 pp.
Context
- Gross margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 98.2%
- Year-over-year change
- -0.4pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 98.2% | -0.4pp |
| FY2024 | 2024-12-31 | 98.6% | +0.7pp |
| FY2023 | 2023-12-31 | 97.9% | -0.5pp |
| FY2022 | 2022-12-31 | 98.4% | -0.3pp |
| FY2021 | 2021-12-31 | 98.7% | — |
Gross Margin vs competitors
How NBIX compares with its peers on the latest reported figures
- NBIX's LTM Sep 2026 gross margin of 97.8% is the highest of the 7 companies compared; the peer median is 90.3%.
- Its year-over-year change of -0.6 pp is the 3rd highest of 6, against a peer median of -1.0 pp.
- Over three fiscal years its change of -0.3 pp compares with a peer median of +3.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 97.8% | -0.6 pp | -0.3 pp | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | 95.0% | — | — |
| LTM Jun 2026 | 93.2% | +1.8 pp | +3.0 pp | |
| LTM Mar 2026 | 92.5% | -1.0 pp | +3.5 pp | |
| LTM Jun 2026 | 88.1% | -0.5 pp | +2.7 pp | |
| LTM Sep 2026 | 64.9% | -27.0 pp | -6.3 pp | |
| LTM Sep 2026 | 64.2% | -21.2 pp | +3.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding NBIX) | 90.3% | -1.0 pp | +3.0 pp | |
Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.13B | 1.49B | 1.89B | 2.36B | 2.86B |
| Cost of Revenue | 14.3M | 23.2M | 39.7M | 34M | 52.1M |
| Gross Profit | 1.12B | 1.47B | 1.85B | 2.32B | 2.81B |
| Gross Margin | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% |
| Research & Development | 328.1M | 463.8M | 565M | 731.1M | 1.02B |
| Selling, General & Admin | 583.3M | 752.7M | 887.6M | 1.01B | 1.16B |
| Operating Expenses | 1.02B | 1.22B | 1.6B | 1.75B | 2.19B |
| Depreciation & Amortization | 10.9M | 15.6M | 21.3M | 27.1M | 30.1M |
| EBITDA | 138.1M | 236.6M | 416.1M | 639.7M | 666.6M |
| EBITDA Margin | 12.2% | 15.9% | 22.0% | 27.2% | 23.3% |
| Operating Income | 102.5M | 249M | 250.9M | 570.5M | 619.1M |
| Operating Margin | 9.0% | 16.7% | 13.3% | 24.2% | 21.6% |
| Interest Income | 0 | 11.2M | 0 | 91M | 90.3M |
| Interest Expense | 25.8M | 7.1M | 4.6M | 126.6M | 0 |
| Other Income / Expenses | (1.1M) | (35.1M) | 81.2M | (84.5M) | 86.3M |
| Income Before Tax | 101.4M | 213.9M | 332.1M | 486M | 705.4M |
| Pre-Tax Margin | 8.9% | 14.4% | 17.6% | 20.6% | 24.7% |
| Income Tax Expense | 11.8M | 59.4M | 82.4M | 144.7M | 226.8M |
| Net Income | 89.6M | 154.5M | 249.7M | 341.3M | 478.6M |
| Net Margin | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
| EPS (Basic) | 0.95 | 1.61 | 2.56 | 3.40 | 4.81 |
| EPS (Diluted) | 0.92 | 1.56 | 2.47 | 3.29 | 4.67 |
| Weighted Avg Shares | 94.6M | 95.8M | 97.7M | 100.4M | 99.5M |
| Weighted Avg Shares (Diluted) | 97.9M | 98.9M | 101M | 103.7M | 102.5M |
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
Intrinsic Alpha fair value
Locked
Current Price
$162.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.